Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

British Journal of Haematology
William I BensingerBrian G M Durie

Abstract

Novel sequential combination therapy for induction may improve the quality of response and therefore prolong survival in newly diagnosed multiple myeloma (MM) patients. We report results from a phase 2 study of two sequential three-drug combinations. Forty-four previously untreated, symptomatic MM patients received: bortezomib 1.3 mg/m(2) (days 1, 4, 8, 11), cyclophosphamide 300 mg/m(2) (days 1, 8), plus dexamethasone 40 mg (day of and day after bortezomib) for three 21-day cycles, followed by bortezomib 1.0 mg/m(2), dexamethasone 40 mg and thalidomide 100 mg daily for three cycles. Overall response rate for 42 evaluable patients was 95%, including 19% stringent complete response (sCR), 26% CR, and 57%>/= very good partial response. Twenty-two patients have undergone stem-cell transplantation. After a median follow-up of 20.9 months, five patients have died; none was induction therapy-related. Median event-free survival (EFS) and overall survival (OS) have not been reached; estimated 1-year EFS and OS rates were 81% and 91% respectively. Both three-drug combinations were well tolerated; 82% of patients completed all six cycles. Toxicities were predictable and manageable; the most-commonly reported grade 3/4 toxicity was neuropa...Continue Reading

References

Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Jul 3, 2007·The Oncologist·Paul G RichardsonKenneth Anderson
Dec 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Bensinger
Mar 26, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarJoan Bladé
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Juan José LahuertaJesús F San Miguel
Nov 14, 2008·Leukemia·A Palumbo, S V Rajkumar

❮ Previous
Next ❯

Citations

Mar 16, 2013·Clinical Medicine Insights. Oncology·Utkarsh Painuly, Shaji Kumar
Apr 6, 2013·Immunotherapy·Alessandra RomanoFrancesco Di Raimondo
Jan 30, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruben NiesvizkyMaureen E Lane
Feb 26, 2011·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·R Schots
Apr 29, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Melissa AlsinaUNKNOWN Resource for Clinical Investigation in Blood and Marrow Transplantation
Sep 29, 2011·Expert Opinion on Pharmacotherapy·Michel Delforge
Aug 2, 2011·Expert Review of Hematology·Javier de la Rubia, Mónica Roig
Dec 5, 2012·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Masafumi Taniwaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.